Although premature children tend to have lower cognitive ability than their peers and 14.9 million are born prematurely each year around the world, is it really possible to stop spontaneous preterm labour? Professor Alfirevic from the Department of Women's and Children's Health at the University of Liverpool explores the pros and cons of delaying preterm delivery.
In an accompanying research paper, Haas and colleagues carried out a review of several controlled trials to determine the most cost-effective tocolytic agent. Tocolytic drugs are used to delay delivery for up to 48 hours. This allows time for doctors to give steroids to speed up the baby's lung development and to enable the mother to be transferred to a centre with a neonatal intensive care unit.
And while Professor Alfirevic appreciates that it is important to choose the right tocolytic drug, he argues that Haas and colleagues' study found no evidence that tocolytic drugs improve rates of newborn illness or death.
Professor Alfirevic suggests that instead of focusing studies on the success of tocolytic drugs on delaying preterm birth, larger trials are needed to determine the clinically meaningful effects of the drugs. He says that clinicians "need proof of a sustained improvement in important health outcomes that matter to women" and the evidence, that tocolytics may allow mothers more time to be moved to specialist neonatal units, may not be enough.
Professor Alfirevic says that despite Haas and colleagues' "well done" meta-analysis, the Royal College of Obstetricians and Gynaecologists' 2011 recommendation that it is reasonable not to use tocolytics still stands.
He concludes that clinicians should be honest and tell women that they are giving them drugs that they hope will prolong pregnancy, but they may not make their babies healthier. And he hopes that "babies are not coming to greater harm by our attempts to keep them in utero."